Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) is the seventh most common type of cancer worldwide accounting for 600.000 new cases and 250.0000 cancer deaths each year [1,2]. At initial diagnoses, ∼40% of patients have early stage disease, ∼50% locally advanced disease and 10% metastatic disease [3]. Despite multimodality treatment with curative intent, at least 50% of initially treated patients develop recurrent or metastatic disease within two years [3]. Patients with metastatic or recu rrent disease that is not amenable to therapy with curative intent have a median overall survival of less than 12 months [4].

Source: Oral Oncology - March 27, 2018 Category: Cancer & Oncology Authors: Saskia H. Hanemaaijer, Stephanie E. van Gijn, Sjoukje F. Oosting, Boudewijn E.C. Plaat, Kirsten L. Moek, Ed M. Schuuring, Bernard F.A.M. van der Laan, Jan L.N. Roodenburg, Marcel A.T.M. van Vugt, Bert van der Vegt, Rudolf S.N. Fehrmann Source Type: research